American Association for Cancer Research
00085472can114199-sup-f3_32k.pdf (32.62 kB)

Supplementary Figure 3 from Integrin α5β1 Plays a Critical Role in Resistance to Temozolomide by Interfering with the p53 Pathway in High-Grade Glioma

Download (32.62 kB)
journal contribution
posted on 2023-03-30, 21:01 authored by Hana Janouskova, Anne Maglott, David Y. Leger, Catherine Bossert, Fanny Noulet, Eric Guerin, Dominique Guenot, Sophie Pinel, Pascal Chastagner, François Plenat, Natacha Entz-Werle, Jacqueline Lehmann-Che, Julien Godet, Sophie Martin, Jan Teisinger, Monique Dontenwill

PDF file - 32K, Nutlin-3a does not modulate the Alpha5 integrin expression in U373 cells



Integrins play a role in the resistance of advanced cancers to radiotherapy and chemotherapy. In this study, we show that high expression of the α5 integrin subunit compromises temozolomide-induced tumor suppressor p53 activity in human glioblastoma cells. We found that depletion of the α5 integrin subunit increased p53 activity and temozolomide sensitivity. However, when cells were treated with the p53 activator nutlin-3a, the protective effect of α5 integrin on p53 activation and cell survival was lost. In a functional p53 background, nutlin-3a downregulated the α5 integrin subunit, thereby increasing the cytotoxic effect of temozolomide. Clinically, α5β1 integrin expression was associated with a more aggressive phenotype in brain tumors, and high α5 integrin gene expression was associated with decreased survival of patients with high-grade glioma. Taken together, our findings indicate that negative cross-talk between α5β1 integrin and p53 supports glioma resistance to temozolomide, providing preclinical proof-of-concept that α5β1 integrin represents a therapeutic target for high-grade brain tumors. Direct activation of p53 may remain a therapeutic option in the subset of patients with high-grade gliomas that express both functional p53 and a high level of α5β1 integrin. Cancer Res; 72(14); 3463–70. ©2012 AACR.